Trials / Withdrawn
WithdrawnNCT05458232
Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- University of Arkansas · Academic / Other
- Sex
- Male
- Age
- 60 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will be the first demonstration of the utility and feasibility of Phosphodiesterase Type 5 inhibitor as an effective pharmacological therapy for improving anabolic resistant states.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tadalafil 5mg | Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days. |
Timeline
- Start date
- 2023-01-20
- Primary completion
- 2023-01-20
- Completion
- 2023-01-20
- First posted
- 2022-07-14
- Last updated
- 2024-11-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05458232. Inclusion in this directory is not an endorsement.